#1 Clinical Trials Search in Europe

Ecoo18A

Recent clinical trials are exploring the potential of ExPEC9V, a novel vaccine containing the ECOO18A component, in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. These studies focus on evaluating the vaccine’s efficacy, safety, and immunogenicity in adults aged 60 and older, particularly those with a history of urinary tract infections. The trials aim to demonstrate the vaccine’s ability to reduce the incidence of invasive E. coli infections and improve the quality of life for vulnerable populations.

Table of Contents

What is ExPEC9V?

ExPEC9V (also known as JNJ-78901563) is an investigational vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults[1]. This vaccine is designed to protect against specific strains of E. coli bacteria that can cause serious infections outside the intestinal tract.

Target Population

The ExPEC9V vaccine is primarily targeted at adults aged 60 years and older who have a history of urinary tract infections (UTIs) in the past two years[2]. This group is considered to be at higher risk for developing invasive E. coli infections.

How ExPEC9V Works

ExPEC9V is a multivalent vaccine, meaning it targets multiple strains of E. coli bacteria. Specifically, it is designed to protect against nine different O-serotypes of E. coli: O1, O2, O4, O6, O15, O16, O18, O25, and O75[1]. These serotypes are commonly associated with invasive E. coli infections.

The vaccine works by stimulating the immune system to produce antibodies against these specific E. coli strains. This prepares the body to fight off these bacteria more effectively if exposed to them in the future.

Clinical Trials

ExPEC9V is currently being studied in large-scale clinical trials to evaluate its effectiveness and safety. Two significant Phase 3 trials are underway:

  1. A study evaluating the co-administration of ExPEC9V with a high-dose quadrivalent influenza vaccine in adults aged 65 years or older[1]. This trial aims to assess whether ExPEC9V can be safely and effectively given alongside the flu vaccine.

  2. A study focusing on adults aged 60 years and older with a history of urinary tract infections[2]. This trial is designed to evaluate the vaccine’s ability to prevent invasive E. coli disease in this high-risk population.

Potential Benefits

If proven effective, ExPEC9V could offer several benefits to older adults:

  • Prevention of invasive E. coli infections, which can be life-threatening in older adults
  • Reduction in hospitalizations related to E. coli infections
  • Decreased risk of complications from urinary tract infections
  • Potential improvement in quality of life for those prone to recurrent UTIs

Safety and Side Effects

As with any vaccine, safety is a crucial consideration. The ongoing clinical trials are closely monitoring for any adverse effects. Common side effects of vaccines may include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Fatigue
  • Headache

The trials are specifically looking at both local reactions (at the injection site) and systemic reactions (affecting the whole body) in the days following vaccination[2].

Conclusion

ExPEC9V represents a promising advancement in preventing invasive E. coli infections in older adults. While still in the clinical trial phase, this vaccine has the potential to significantly reduce the burden of these serious infections in a vulnerable population. As research progresses, more information about its effectiveness and safety profile will become available.

If you’re interested in learning more about ExPEC9V or are considering participating in a clinical trial, it’s important to discuss this with your healthcare provider. They can provide personalized advice based on your individual health status and risk factors.

Aspect Details
Vaccine Name ExPEC9V (containing ECOO18A component)
Target Population Adults aged 60 years and older with a history of urinary tract infections
Primary Objectives Evaluate efficacy in preventing invasive E. coli disease, assess safety and immunogenicity
Administration Single intramuscular injection
Key Endpoints Reduction in IED events, UTIs, hospitalizations, and improvement in quality of life
Study Design Randomized, double-blind, placebo-controlled Phase 3 trials
Potential Benefits Reduced incidence of invasive E. coli infections, fewer hospitalizations, improved quality of life

FAQ

  • What is ExPEC9V and what is it designed to prevent? ExPEC9V is a vaccine designed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. It contains multiple components, including ECOO18A, which target different strains of E. coli that can cause serious infections outside the intestinal tract.
  • Who is being studied in these clinical trials? The clinical trials are focusing on adults aged 60 years and older, particularly those with a history of urinary tract infections in the past two years. This group is considered at higher risk for invasive E. coli infections.
  • What are the main objectives of these clinical trials? The main objectives are to evaluate the efficacy of ExPEC9V in preventing invasive E. coli disease, assess its safety and immunogenicity, and determine its impact on health-related quality of life in the target population.
  • How is the vaccine administered? ExPEC9V is administered as an intramuscular injection. In the trials, participants receive either the vaccine or a placebo in a single dose.
  • What are the potential benefits of this vaccine if successful? If successful, ExPEC9V could significantly reduce the incidence of invasive E. coli infections, including urinary tract infections, bloodstream infections, and sepsis in older adults. This could lead to fewer hospitalizations, improved quality of life, and potentially reduced mortality related to these infections.

Ongoing Clinical Trials on Ecoo18A

  • Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of ExPEC9V vaccine for preventing invasive E.

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany The Netherlands Spain +1

Glossary

  • ExPEC9V: A vaccine containing multiple components, including ECOO18A, designed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease.
  • Extraintestinal pathogenic Escherichia coli (ExPEC): Strains of E. coli bacteria that can cause infections outside the intestinal tract, such as urinary tract infections, bloodstream infections, and sepsis.
  • Invasive E. coli Disease (IED): A serious infection caused by E. coli bacteria that spreads beyond the initial site of infection, such as the urinary tract, into the bloodstream or other normally sterile sites in the body.
  • Urinary Tract Infection (UTI): An infection that affects any part of the urinary system, including the kidneys, ureters, bladder, and urethra, most commonly caused by bacteria like E. coli.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the experimental treatment.
  • Efficacy: The ability of a treatment or intervention, such as a vaccine, to produce the desired result under ideal conditions in a clinical trial.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys, potentially causing severe complications if left untreated.

References

  1. http://clinicaltrials.eu/trial-id/2023-504168-40-00
  2. http://clinicaltrials.eu/trial/study-on-jnj-78901563-vaccine-for-preventing-invasive-e-coli-disease-in-adults-60-with-recent-urinary-tract-infections/